Monday, May 9, 2016

UPDATE 1-NewLink's pancreatic cancer therapy fails late-stage study

May 9 (Reuters) - NewLink Genetics Corp said on

Monday its experimental pancreatic cancer immunotherapy did not

meet the main goal in a late-stage study, sending its shares

tumbling 36 percent in...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)